Head, North America Medical Affairs for Self-Care
Kenvue Brands LLC
Fort Washington, Pennsylvania
As Head of North America Medical Affairs for self-care products, Dr. Budnitz seeks to bridge scientific research, clinical development, and commercialization by providing objective, unbiased information and education to healthcare professionals and other stakeholders in order to ensure the safe and effective use of Kenvue products, including Tylenol, Motrin, Zyrtec, Pepcid, and many others. Previously, Dr. Budnitz led Kenvue’s Global Safety Risk Assessment Team which provides the medical oversight for assessing and characterizing the safety profile of the drugs and device components of Kenvue products.
Prior joining Kenvue, Dan served in the U.S. Public Health Service for 21 years, including 17 years as the founding Director of the Medication Safety Program at the U.S. Centers for Disease Control and Prevention (CDC), where he led outbreak investigations, public health emergency responses, and designed and implemented a national adverse drug event surveillance system (NEISS-CADES). He also launched the public-private PROTECT Initiative that seeks to reduce medication ingestions and errors in young children, and which introduced him to the potential for industry-based innovation initiatives designed to foster public health and safety. He has authored 99 scientific publications with a focus on public health surveillance and outpatient drug safety, including seminal works on the opioid overdose epidemic and non-opioid analgesic safety. He has served as both a presenting expert and a voting member of numerous FDA Advisory Committees.
Dan received an AB (Government) from Harvard University and an MD-MPH from Emory University as a Woodruff Scholar. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and has practiced as a board-certified internal medicine physician in the Emory/Grady Health System and at the Atlanta VA Medical Center.
Thursday, September 4, 2025
4:00 PM - 5:30 PM PST
Thursday, September 4, 2025
4:00 PM - 5:30 PM PST